内毒素
< 0.1 EU/μg of the protein by LAL method.
制剂
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation.
描述
Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Ile 56 - Glu 182) of human DR5 (Accession #NP_003833.3) fused with a 6×His tag at the C-terminus.
储存
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。
生物活性
1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human TRAIL at 2 μg/mL (100 μL/well) can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.
2.Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 0.38-1.5 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.
3.Measured by its binding ability in a functional ELISA.Immobilized Human TRAIL / TNFSF10 Protein at 2μg/mL (100 μL/well) can bind Human CD262 Protein with a linear range of 0.5-14.1 ng/mL.
复溶
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。
请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！
This protein is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.
